Rob Ter Heine
Nijmegen, GE 6525GA, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 197 publications
Correction: Model‑Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness.
Journal: Clinical pharmacokinetics
Published: May 19, 2026
Dosing challenges for chemotherapy and immunotherapy in congenital achondroplasia: a case report and literature review.
Journal: Cancer chemotherapy and pharmacology
Published: April 29, 2026
Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumab.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 10, 2026
Population pharmacokinetics of total and free mycophenolic acid in plasma in paediatric patients with nephrotic syndrome including salivary concentrations and the pharmacodynamics.
Journal: Pharmacological reports : PR
Published: March 26, 2026
Correction: Model‑Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness.
Journal: Clinical pharmacokinetics
Published: March 12, 2026
Pre-treatment T cell phospho-signalling identifies clinical pembrolizumab response in non-small cell lung cancer patients.
Journal: International immunopharmacology
Published: March 02, 2026
Translational modelling challenges receptor‑occupancy‑based dosing of PD‑1 inhibitors like pembrolizumab.
Journal: British journal of cancer
Published: February 25, 2026
Defining the unbound target exposure of teicoplanin, Part 1: Insights from the hollow-fibre system.
Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Published: February 03, 2026
Subcutaneous versus intravenous ultra-low dose rituximab in rheumatoid arthritis: a randomised controlled PK-PD non-inferiority trial.
Journal: Rheumatology (Oxford, England)
Published: February 03, 2026
Defining the unbound target exposure of teicoplanin part 2: Dose individualization through population pharmacokinetic modelling.
Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Published: February 03, 2026
Deprescribing opportunities for patients with advanced non-small cell lung cancer: an observational study of potentially inappropriate medications and stakeholders' perspectives.
Journal: International journal of clinical pharmacy
Published: January 20, 2026
Last Updated: 09/26/2026